	US 11,999,750 B2
	Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
Anantha Sudhakar, South San Francisco, CA (US)
Assigned to DENALI THERAPEUTICS INC., South San Francisco, CA (US)
Filed by Denali Therapeutics Inc., South San Francisco, CA (US)
Filed on Jan. 11, 2023, as Appl. No. 18/095,621.
Claims priority of provisional application 63/386,113, filed on Dec. 5, 2022.
Claims priority of provisional application 63/298,816, filed on Jan. 12, 2022.
Prior Publication US 2023/0271978 A1, Aug. 31, 2023
Int. Cl. C07D 498/04 (2006.01); A61K 31/553 (2006.01); A61P 29/00 (2006.01)

CPC C07D 498/04 (2013.01) [C07B 2200/13 (2013.01)]

18 Claims

1. A crystalline form selected from the group consisting of:

Form A of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;

Form B of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;

Form C of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;

Form D of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;

Form E of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; and

Form F of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide.